Butantan-Dengue Vaccine in Children and Adults | NEJM

A single-dose vaccine that offers protection against all four dengue virus serotypes without regard to dengue baseline serostatus and across a wide age range is needed.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/3vTJ3Qu

[@Zehh35]

Very important work! Will help saving many lives in endemic areas

[@Zehh35]

At 1:31 the Y-axis shows "Vaccine efficacy" while it should state something related to adverse event prevalence

[@PhilipposACosta]

Very good.
How about clinical outcomes?

[@leandromantovani4282]

You need to specify what kind of efficacy are you talking about, if it’s the relative risk reduction (RRR ) or the absolute risk reduction (ARR) , because the ARR always comes lower but it’s not suitable for being manipulated in order to alter the outcome by choosing an specific test group like the RRR is and also is required by the FDA’s guidelines to be informed on all relevant information about medication and vaccines, it is enough of strategies to create misunderstandings among the population i want the whole truth!

[@balasundaram7781]

🎉❤